drugset / Trial / NCT05112692
Progestin-primed Ovarian Stimulation Protocol Versus GnRH Antagonist Protocol in Polycystic Ovary Syndrome Patients Undergoing IVF/ICSI Cycles
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this trial is to compare the efficacy and safety of the PPOS protocol to the GnRH antagonist protocol in patients with PCOS who are undergoing IVF/ICSI cycles.
Timeline
- Start
- 2021-11
- Primary completion
- 2023-11
- Completion
- 2023-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cetrorelix | Other / unclassified | 0.25 mg | Subcutaneous |
| Comparator | Dydrogesterone | Other / unclassified | 20 mg | Oral |
| Comparator | Progesterone | Other / unclassified | — | — |
| Comparator | Triptorelin | Other / unclassified | 0.1 mg | Subcutaneous |
| Comparator | estradiol valerate | Unknown | — | Oral |
| Comparator | human chorionic gonadotropin | Protein / enzyme biologic | 150 iu | Intramuscular |
| Comparator | human chorionic gonadotropin | Protein / enzyme biologic | 225 iu | Intramuscular |
| Comparator | human chorionic gonadotropin | Protein / enzyme biologic | 1000 iu | Intramuscular |